|
|
|
|
|
Genome Res. 14:2190-2200, 2004 ©2004 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/04 $5.00 Resources The Pseudomonas aeruginosa PA01 Gene Collection1 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Institute of Proteomics, Cambridge, Massachusetts 02141, USA 2 Department of Microbiology, Harvard Medical School, Institute of Proteomics, Cambridge, Massachusetts 02141, USA
Pseudomonas aeruginosa, a common inhabitant of soil and water, is an opportunistic pathogen of growing clinical relevance. Its genome, one of the largest among bacteria [5570 open reading frames (ORFs)] approaches that of simple eukaryotes. We have constructed a comprehensive gene collection for this organism utilizing the annotated genome of P. aeruginosa PA01 and a highly automated and laboratory information management system (LIMS)-supported production line. All the individual ORFs have been successfully PCR-amplified and cloned into a recombination-based cloning system. We have isolated and archived four independent isolates of each individual ORF. Full sequence analysis of the first isolate for one-third of the ORFs in the collection has been completed. We used two sets of genes from this repository for high-throughput expression and purification of recombinant proteins in different systems. The purified proteins have been used to set up biochemical and immunological assays directed towards characterization of histidine kinases and identification of bacterial proteins involved in the immune response of cystic fibrosis patients. This gene repository provides a powerful tool for proteome- and genome-scale research of this organism, and the strategies adopted to generate this repository serve as a model for building clone sets for other bacteria.
The highly adaptable bacterium Pseudomonas aeruginosa inhabits a wide range of environmental niches and causes disease in many species, including humans. This organism leads to a variety of infections in immunocompromised patients as well as destructive chronic respiratory disease in individuals with cystic fibrosis (Ratjen and Doring 2003
The coding capacity of the relatively large genome of P. aeruginosa, which exceeds 6000 kb for most strains, is thought to contribute to its versatility. P. aeruginosa thus has the potential for expressing a proteome comparable in size and complexity to simple eukaryotes. The genomic repertoire of P. aeruginosa specifies functions that promote survival in diverse environments from the soil and water to respiratory tissue and blood. Relevant to its role as an opportunistic human pathogen are a large number of genes encoding virulence factors, conserved in all strains (Wolfgang et al. 2003 The difficulty in controlling P. aeruginosa infections using conventional antibiotic therapy results in part from an over-abundance of genetic determinants for drug effluxing systems in the genome, such as the presence of 12 members of the resistance-nodulation-cell division (RND) family of multisubunit efflux pumps. The reason for this apparent redundancy of related or identical functions is unclear. One possible explanation for the occurrence of such paralogs holds that they are all differentially regulated enabling survival in various environmental niches. Alternatively, the paralogs may allow for evolutionary fine-tuning of specific but related biochemical activities.
Given its importance as a human pathogen and as an example of a highly adaptable prokaryote, P. aeruginosa exemplifies a useful model organism for the high-throughput (HT) functional analysis of proteomes. The creation and validation of a comprehensive collection of expression-ready genes would provide an important starting point for this approach by enabling the parallel analysis of many or all proteins in a broad variety of experiments. This gene or open reading frame (ORF) collection would allow researchers to: screen for functional activities of interest (Zhu et al. 2001 An ideal collection of such clones would embody the following virtues: the clone set should be (1) comprehensive; (2) flexible and amenable for many experimental systemsallowing expression from various promoters, on different plasmid backbones, and with peptide tags fused to the ends of the proteins if desired; (3) in protein expression-ready format (i.e., include only coding sequences); (4) catalogued and trackableallowing for the rapid re-array of relevant subsets of clones as needed; and (5) clonally isolated and sequence verifiedallowing the unambiguous assignment of function or property to a specific coding sequence. With such a catalogued clone set, saturating screens that survey the proteome can be performed with efficiency, hits can be identified easily, and, importantly, information regarding all clones (even those with no response) can be extracted and their significance assimilated. In order to facilitate an understanding of the development of multidrug-resistant P. aeruginosa strains and to aid in the development of a useful vaccine, we have undertaken the development of a gene repository for this organism. This resource would facilitate research in all aspects of basic biology and pathogenesis as well as facilitate the development of novel strategies directed towards the understanding and clinical management of this organism. Here we describe the construction of the gene repository for this pathogen, based on the genome of P. aeruginosa PAO1. The 5570 annotated ORFs were amplified and cloned using a recombinational cloning system (Gateway, Invitrogen). Several expression platforms were tested for two sets of genes from the repository in order to validate the clones and to assess the feasibility of using the repository for HT biochemical and immunological studies.
Project Overview The creation of the P. aeruginosa gene repository occurred in three phases: (1) Preproduction and Development, (2) Production, and (3) Postproduction and Validation. The Preproduction and Development phase focused on several areas including importing and processing the relevant bioinformatics regarding the organism's annotated genome, predicting and organizing a complete set of PCR primers, establishing optimal biochemical conditions and standard operating procedures (SOPs) for the production phase, and settling on a final workflow. Figure 1A shows a schematic representation of the final workflow used in the creation of this repository. During the Production phase, we used our established automated clone production pipeline and laboratory information management system (LIMS), achieving a final throughput of four 96-well plates of genes per week. All processes were carried out in bar-coded containers and tracked by the Oracle-based database at both sample and plate levels along with any relevant process results (gel images, PCR success, colony count, etc.). The Postproduction and Validation phase focused on re-arraying the relevant clones, producing archival sets, and verifying the full-length sequences of the clones.
Populating the LIMS with P. aeruginosa Data The first step in creating the repository was acquiring the genome sequence information and annotation for the complete set of predicted ORFs for this organism. Complete sequencing and analysis of the P. aeruginosa PA01 genome was completed and published in 2000 (Stover et al. 2000
Oligonucleotide Design and Gene Amplification Amplification of the predicted ORFs was carried out by a strategy using two consecutive rounds of PCR amplification (Fig. 2B). The first round of PCR was executed using genomic DNA as template and a pair of matched 5' and 3' oligonucleotides containing gene-specific sequences and a short sequence matching part of the attB1 and attB2 sequences, respectively. In the second PCR reaction, the rest of the attB sites were added by using the product of the first PCR reaction as template along with primers containing complete attB1 and attB2 sequences which overlapped the first-round primers. This two-step PCR approach represents an alternative to one-step PCR that efficiently produces entry clones for the Gateway system. By requiring shorter primers for amplification of the target genes it significantly reduces the cost of the primers, which was the single most expensive reagent associated with the construction of this gene repository. More importantly, we found that using shorter oligos reduces the incidence of nucleotide misincorporations and `N - 1' products associated with synthesis of long oligonucleotides. Finally, detailed quality control could be run on a single lot of attB primers, which was then used for all reactions, thus ensuring consistent conditions. Pairs of oligonucleotides for PCR amplification of each of the 5570 ORFs were automatically calculated by software developed in-house (www.hip.harvard.edu, click on Informatics then Programs) that uses the nearest-neighbor algorithm to create primer pairs with a specified Tm for the gene-specific sequences that are anchored at either end of the coding sequence followed by appending the partial attB tails. Based on the high GC content of this bacterial genome (66% GC-rich) and on preliminary data obtained during PCR optimization studies, the melting temperature for the gene-specific part of the primers was set at 65°C. The forward primers were designed to provide a uniform initiating codon (ATG) for all ORFs. In addition, sequences specifying a ribosome binding site (RBS) and an optimal Kozak sequence were introduced at the appropriate positions between the ATG and the recombination site (see Methods for representative examples of forward and reverse primers). The reverse primers were designed to replace the respective stop codon with the glycine codon (GGA), thus allowing read-through and the addition of C-terminal tags if desired. The primer design thus resulted in the following configuration: attB1-RBS-Kozak-ORF-attB2, with all the initiating codons normalized to ATG and all stop codons converted to GGA (Fig. 2B). A total of 11,140 oligonucleotides (in well-position matched sets of forward and reverse primer plates) were obtained (Operon). Depending on the protein expression vector used, this arrangement allows for the addition of N-terminal tags, C-terminal tags or both. It should be noted that because there is no stop codon, there is a minimum of eight amino acids that will always be appended to the C-terminal end of the protein, which correspond to the amino acids encoded by the recombination site. In addition, when N-terminal tags are desired, additional residues will be added between the end of the tag and the initiation codon of the gene. These residues correspond to the amino acids encoded by the recombinant site and by the sequences of the introduced RBS and Kozak sequences. Despite these anticipated compromises, we felt that this offered the most versatile configuration for this clone set. To establish optimal conditions for the PCR amplification step, a set of 10 Pseudomonas genes, representing a range of sizes, were selected and tested using 50 ng of genomic DNA from P. aeruginosa PA01 and DNA polymerases from different suppliers. We obtained the best success rate using the GC-Rich enzyme mix from Roche (data not shown). Additional optimization revealed that increasing the MgCl2 concentration to 2 mM provided better success and yields (see Fig. 3A). In preliminary tests, the nucleotide misincorporation rate for this enzyme at the higher magnesium concentration was equivalent to that obtained under standard conditions (1 mM MgCl2), establishing that the dramatically better PCR success outweighed concerns about reduced fidelity. Next, we validated the PCR protocol by targeting a full plate of genes with a CDS range from 200 to 2700 nucleotides: 100% success rates were obtained for both PCR and BP capture based on gel analysis of the PCR reactions and insert analysis of the clones resulting from the BP reactions, respectively (data not shown).
We then used these PCR conditions for the amplification of the 5570 ORFs. We monitored the PCR results for every reaction for the first twelve 96-well plates using an automated agarose gel system developed in the lab (with capacity for 192 Samples). Given the high PCR success rate (99%) and uniformity of the PCR reactions observed (see Fig. 3B), for the remainder of the reactions we used a sampling approach wherein randomly selected samples from each plate were run on diagnostic gels to monitor PCR success.
Cloning of PCR Products
A second round of cloning was then initiated to capture the 183 genes that failed to generate clones during the first round of cloning. To determine whether these genes had failed the PCR amplification step, aliquots of the original PCR reactions were analyzed by agarose electrophoresis. Repeat capture reactions were run for the 60% of these that demonstrated PCR product, and for the remaining clones both PCR and capture reactions were repeated. This yielded 104 additional genes. In the third and final round of cloning, we identified and worked with those genes that failed all previous cloning attempts. This group contained some of the largest genes of this organism (genes larger than 5.5 Kb) and had escaped amplification during the two previous attempts. We successfully amplified them by extending the duration and number of PCR cycles for this group. Despite the PCR success, it was often difficult to capture the genes by recombination because of the decreased efficiency of the Clonase reaction to large inserts. Nevertheless, this third round of cloning eventually resulted in the amplification and capture of all the targeted genes and thus successfully completed the cloning phase of the project (Table 1). Three copies of the complete repository, each containing 22,280 clones, were generated and archived in three different locations, two in Boston and one in Marseille, France. In addition, subsets of genes have been pulled out of the collection at different times, characterized (as shown below) and distributed to various labs in both entry (pDONR201) and bacterial expression vectors for use in different assays.
Sequence Validation of Clones
Our criteria for acceptance of clones were as follows. First, the entirety of the gene had to be fully covered by high-quality sequence reads (Phred quality scores The first objective of the sequence analysis was to identify and retrieve acceptable clones. The second objective was to identify those clones that required additional sequencing, either to fill gaps or to analyze alternate isolates because the first isolate was rejected by the above criteria. Analysis of the sequencing data indicated that 89.0% of the clones were fully covered by high-quality sequence; 6.8% of the clones were only partially sequenced or lacked good-quality reads; and 4.2% of the clones did not yield sequence information due to lack of culture growth. The latter two groups were not considered further in the analysis. Of the clones with good sequence coverage, 99% corresponded to the correct reference sequence, and the remaining 1% all showed 30%-40% homology to the expected gene, but 100% homology to a different gene in the collection.
Of the clones that were fully sequenced, 80% were acceptable by the criteria listed. The results of the sequence analysis are shown in Figure 4. About half of the clones (52%) showed no discrepancies, and the other half (48%) contained discrepancies that result in silent or missense mutations. Unacceptable discrepancies that lead to gross changes in the polypeptide caused 17% of the fully sequenced genes to be rejected. We estimate the error rate of this enzyme to be
Using this strategy of analyzing one isolate per gene, we were able to accept clones for 70% of the genes submitted for sequencing. Preliminary sequence analysis from a test set of 208 genes (with CDS length up to 2500 bp) for which all four candidate clones were examined revealed a high probability (99%) of identifying an acceptable clone from the archived isolates (data not shown). We are in the process of completing the sequencing of the first candidate for the remaining genes in the collection and the remaining candidates for those genes with unacceptable or uncovered clones from the first round of sequencing.
Protein Expression and Purification
Protein expression in bacteria of the response regulator gene set with N-terminal 6xHis- and GST-tags resulted in 90% and 95% success rates, respectively, as judged by SDS-PAGE and Coomassie Blue staining of the total extracts (Fig. 5; Supplemental Table I). Under nondenaturing conditions we found that 75% of the GST-recombinant proteins could be purified from the soluble fraction, whereas only 30% of the 6xHis-tagged proteins were soluble. In contrast, under denaturing conditions 100% of the His-tagged proteins could be recovered and purified (Supplemental Table I). These data are in keeping with earlier results on the relatively poor efficiency of recovering soluble proteins tagged with the His tag compared to those with the GST tag (Braun et al. 2002
The use of cell-free protein expression systems offers an appealing alternative to in vivo expression, particularly in the HT context. As cell-free systems use pre-made and characterized extracts, they avoid the need to transform, grow, induce, and lyse cells. To determine the applicability of this technology for characterization of our clones, we have successfully adopted Yokoyama's protocol (Kigawa et al. 1995 The 89 genes in the second gene set (Supplemental Table II) were subcloned and expressed in BL21DE3 cells as N-terminal 6xHis-fusions. The relative success rates for expression of nonmembrane- and membrane-associated proteins were 91% and 59%, respectively (Supplemental Table II). Furthermore, the 90% success rate for expression of soluble proteins agrees with the rate obtained for the response regulator gene set described above (which is composed of soluble proteins). Figure 6 shows the IMAC purification results for the 67 expressed proteins that were employed in the ELISA assay described below.
Assays Using Recombinant Proteins Developing a Histidine Kinase Substrate Assay Bacteria use two-component systems to sense and respond to changes in their environments. In P. aeruginosa, a number of two-component systems have been shown to be involved in signal transduction, regulating the expression of diverse genes, particularly those encoding virulence factors. These include control of expression of fimbrial and flagellar components (Ishimoto and Lory 1992
Prototypically, the two-component system is composed of two proteins, a response regulator and a histidine kinase (usually membrane-associated). Upon stimulation, the histidine kinase undergoes autophosphorylation at a histidine residue, followed by transfer of the phosphate to an aspartic acid on the response regulator. The phosphorylated response regulator stimulates the transcription of target genes by binding to their regulatory sequences (Stock et al. 2000
We sought to develop an in vitro system to screen for substrates of the response regulator kinases. In order to establish the conditions for detecting kinase activity, we chose three kinases: two well characterized kinases, PhoQ (PA1180) and PilS (PA4546), and the putative "orphan" kinase PA4036. Guided by prediction algorithms of secondary structures and transmembrane domains and experience with PilS (Boyd and Lory 1996
In order to generate substrates and conditions to measure PilS histidine kinase activity, we isolated and subcloned all of the 71 genes encoding for the predicted P. aeruginosa response regulators, including the bona fide substrate of this enzyme, PilR (Supplemental Table II; Fig. 5). For the kinase assays described here, all 71 response regulators were subcloned into a C-terminal GST-fusion vector with a T7 promoter (pANT7cGST) and were expressed using the rabbit reticulocyte system (Promega). Protein expression levels were assessed by western blot using anti-GST antibodies (Supplemental Fig. 1). In our initial experiments we immobilized a set of seven proteins to 96-well anti-GST plates to measure their ability to act as substrates of the PilS kinase. Figure 7C shows the relative levels of phosphorylation of the bona fide substrate of this enzyme, PilR, as well as that of the other response regulators after correcting for the amount of substrate used in the assay. As expected, our positive control, PilR, demonstrated a strong signal. Interestingly, another response regulator, PA2824, was phosphorylated nearly as strongly, and a third, PA4843, showed above-background incorporation of phosphate. These findings suggest that PilS (and potentially other histidine kinases) can phosphorylate alternative substrates at rates similar to that of their bona fide substrates. The physiological relevance of the phosphorylation of PA2824 by PilS is currently being evaluated at the genetic level.
Developing an Immune Response Assay
Genome sequencing projects have produced an immense amount of information regarding the organization, evolution, and coding capacity of the various genomes covered. All this has propelled a trend in biology to address scientific questions on a whole-cell or system-wide basis, in contrast to the classical reductionistic approaches. There is an ever-increasing need to develop tools and resources that can build on the genome information and facilitate the understanding of the biological function of the thousands of uncharacterized gene products that have been identified through sequencing. Technologies such as DNA microarrays have been developed and successfully applied to analysis of gene expression at the RNA level (Brown and Botstein 1999 The use of bacteria as model systems to begin developing HT tools for studying protein function offers a number of advantages. More than 600 bacterial genomes have been sequenced or are near completion (http://wit.integratedgenomics.com/GOLD), leading to excellent tools and predictive methods for identifying protein-encoding ORFs. The genetic tractability and manageable genome size of bacteria facilitate experimentation and hypothesis testing. Moreover, the study of Pseudomonas in particular offers the opportunity to understand its virulence, its ability to evade antimicrobials, and its interaction with the host response. Nearly half of its predicted ORFs have no assigned function, and novel tools are needed to identify both vaccine candidates and new targets for therapeutic intervention. The creation of a repository of well characterized clones provides an opportunity to develop these tools and employ them in discovery.
We used the annotated P. aeruginosa PA01 genome sequence (Stover et al. 2000
The mutation rate of 1 error every 450 bases observed for this project is notably higher than we have observed in other cloning projects in our lab. This high mutation rate is a result of the necessity to use a polymerase and PCR conditions that allowed the amplification of the high-GC-content ORFs of this organism. On the other hand, the intrinsic organization of the P. aeruginosa genome (as well as those of other prokaryote organisms) facilitated several of the steps involved in the construction of the repository. The high density of coding regions and the absence of introns in the bacterial genomes allowed the use of genomic DNA preparations as template for the PCR amplification of genes. Genomic DNA is an ideal PCR template because it is perfectly normalized and easy to prepare in high quantities. Thus, ample template can be added to all reactions allowing for a reduction in amplification cycles, which in turn reduces the frequency of mutations. PCR conditions were identified that gave a very high hit rate,
The transfer of over 150 genes of interest to several protein expression vectors demonstrates the ease with which these clones can be used to subclone into virtually any vector. Expression levels for these recombinant proteins as hybrid proteins fused at their N-termini to 6x-His or GST are comparable to those observed in the lab for clones from other collections produced in the Gateway system such as our human clones (Braun et al. 2002 Furthermore, we have demonstrated the feasibility of using these expressed proteins in two important aspects of therapeutic discovery regarding Pseudomonas. In the first, an HT format for immunodetection assays was used to probe the sera of patients with CF for the presence of antibodies to P. aeruginosa proteins. Sera from CF patients displayed immunoreactivity against a number of the tested P. aeruginosa proteins that were not detected in noninfected individuals. These included reactivity to several components of the type III secretion apparatus located on the outer surface of bacteria, as well as secreted proteins such as ExoS and ExoA. Experiments are currently underway to expand the scale of this approach in order to examine the proteome of Pseudomonas for potential immundominant antigens. Correlating the immune response to specific components of the bacterial proteome with the clinical condition of individual patients may serve as a useful guide in selecting proteins suitable for vaccine development. In a second approach, we used active purified PilS histidine kinase to probe a collection of response regulators of the two-component signal transduction system to identify potential substrates. In addition to its bona fide substrate PilR, two other putative substrates were identified. Based on the existing annotation for these genes, one of the phosphorylated proteins (PA 2824) is a probable sensor/response regulator hybrid, and the second one (PA 4843) is a probable two-component response regulator. Further disruptions of these genes and analysis of the mutants in the context of PilS stimulation is underway to validate these findings.
It is apparent that added power can be brought to the body of information generated by various genome-sequencing projects by using this information to create tangible tools to study the functions of the proteome. With a resource that enables the expression of all proteins in the proteome, it will be possible to execute experiments that probe the myriad of protein activities extant in the cell, providing an opportunity to functionally annotate many of the predicted ORFs for which there is no assigned biochemical function. Here we report the creation of one such resource, a gene repository for P. aeruginosa, an opportunistic human pathogen. This type of repository will greatly accelerate research in various areas of functional proteomics. Moreover, this resource can provide important tools for investigations in more applied fields of vaccines and anti-infective agents. This type of gene repository will also facilitate the identification of protective antigens by "reverse vaccinology" and "genetic vaccination" approaches (Masignani et al. 2002
Preparation of Genomic DNA from Pseudomonas aeruginosa Pseudomonas aeruginosa PA01 was streak-purified in an LB/agar plate, and a single colony was isolated and grown overnight at 37° C in 15 mL of LB. The cells were harvested by centrifugation, and the resulting pellet was resuspended and washed twice with TE (pH 8.0). The cells were then resuspended in 5 mL of TE and lysed by adding 50 µL of 20% SDS solution and gently inverting the tubes a few times. Proteins in the lysate were digested by adding 50 µL of 20 mg/mL proteinase K solution, followed by incubation at 37° C for 1 h. The lysate was extracted with phenol, phenol/chloroform/iso-amyl alcohol, and chloroform. Genomic DNA was precipitated by gentle adding and mixing 2 volumes of ethanol (EtOH). Strings of genomic DNA were harvested with a glass pipette and then extensively washed with a 70% ethanol solution. Finally, the DNA was air dried and dissolved in TE. The concentration of DNA was determined by OD at 260 nm.
Oligonucleotide Design and Synthesis An example of a typical set of gene-specific primers is given below. The gene-specific portion of the oligos is underlined. The rest of the sequence corresponds to the partial attB sequences. Initiation (ATG) codon and complementary sequence for Gly codon (substituting the natural STOP codon) are indicated in bold: Forward primer: 5'-AAAGCAGGCTCCGAAGGAGATAC CATGAGCGAAACGCCCTCCCCCGC-3' Reverse primer: 5'-AGAAAGCTGGGTCTCCGCCGCACAGATAGGTACCGGTAC-3' The primer sequences were arranged automatically on corresponding plates, one 5' set and one 3' set, with each primer sequence pair on the same position for each plate. Next, 50 nmol scale synthesis of the oligonucleotides was carried out by OPERON, and oligos were delivered in normalized 50 µM solutions in bar-coded 96-well plates. A unique set of primers was used for all of the PCR 2 reactions in order to reconstruct the attB sites. Regions of overlap with the PCR 1 primers are underlined. attB1primer: 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGAAGGAGAT-3' attB2 primer: 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCC-3'
Amplification of ORFs The second PCR reaction was carried out in a 50 µL volume containing 3 µL from the first PCR reaction (as template), 0.5 µM attB primers, 1 U GC-Rich Enzyme (GC-RICH PCR System from Roche), 200 µM of each dNTP, 1 x GC-Rich Buffer #2, 0.5 x GC-Rich Buffer #3, and MgCl2 adjusted to 2 mM. Thermocycling was performed using an initial denaturation step at 94°C for 4 min, followed by 15 cycles of denaturation at 94°C for 1 min, annealing at 65°C for 45 sec, and elongation at 72°C for 5 min. A final incubation at 72°C for 10 min was then added.
Capture of Amplified ORFs
Preparation of E. coli-Competent Cells
Transformation of PEG/DMSO-Competent Cells and Isolation of Clones
Subcloning of ORFs Into Expression (Destination) Vectors
Bacterial Expression and Purification of Proteins
Western Blot Analysis
Construction and Production of Histidine Kinase Deletion Mutants
Kinase Assays Phosphorylation of the response regulator proteins was carried out by incubating PilS with GST-tagged response regulator proteins immobilized in the wells of 96-well plates. Response regulators in a Gateway converted-pCITE-GST were expressed using a rabbit reticulocyte system (Promega). Then, 15 µL of the extracts were transferred to individual wells of a 96-well plate coated with anti-GST antibodies (Amersham) and incubated at 15°C for 2 h. Plates were then washed with PBS and incubated with blocking buffer (5% nonfat dry milk, 0.2% Tween 20 in PBS). Amounts of proteins bound to the wells were estimated by incubating the wells with monoclonal anti-GST antibodies (Cell Signalling), followed by detection with anti-mouse HRP-conjugated IgG antibodies. (Amersham) using pico ELISA ECL reagents (Pierce). Phosphorylation of the immobilized proteins was carried out by adding 50 µL of autophosphorylated PilS to each well and allowing the reaction to proceed for 30 min. Conditions of the assay were exactly as described above for autophosphorylation reactions. Phosphorylation was terminated by removing the kinase solution and washing the wells with PBS/0.05% Tween 20. The incorporated radioactivity was then determined by scintillation counting and corrected by the amount of protein present in each well (as determined by the anti-GST determination described above).
ELISA Assays
LIMS
We thank all past and present members of the Institute of Proteomics who have contributed to the development of the techniques that made this work possible. Special thanks to Dr. Gerald Marsischky for helpful discussions and advice all along this project. We thank Andreas Rolfs for organizing the rearray and submission of clones for sequencing. This work has been supported by grant LORY00V0 from the Cystic Fibrosis Foundation and by funds from the Harvard Medical School.
3 Corresponding author. E-MAIL lbrizuela{at}hms.harvard.edu; FAX (617) 324-0824. [Supplemental material is available online at www.genome.org.] Article and publication are at http://www.genome.org/cgi/doi/10.1101/gr.2482804.
Banwart, B., Splaingard, M.L., Farrell, P.M., Rock, M.J., Havens, P.L., Moss, J., Ehrmantraut, M.E., Frank, D.W., and Barbieri, J.T. 2002. Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of Pseudomonas aeruginosa. J. Infect. Dis. 185: 269-270.
Boyd, J.M. and Lory, S. 1996. Dual function of PilS during transcriptional activation of the Pseudomonas aeruginosa pilin subunit gene. J. Bacteriol. 178: 831-839.
Braun, P., Hu, Y., Halleck, A., Shen, B., Harlow, E., and LaBaer, J. 2002. High-throughput purification of human proteins from bacteria. Proc. Natl. Acad. Sci. 99: 2654-2659. Brauner, A., Cryz, S.J., Granstrom, M., Hanson, H.S., Lofstrand, L., Strandvik, B., and Wretlind, B. 1993. Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 12: 430-436.[CrossRef][Medline] Brizuela, L., Braun, P., and LaBaer, J. 2001. FLEXGene Repository: From sequenced genes to gene repositories for high-throughput functional biology and proteomics. Mol. Biochem. Parasitol. 118: 155-165.[CrossRef][Medline] Brown, P.O. and Botstein, D. 1999. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21: 33-37.[CrossRef][Medline]
Deretic, V., Dikshit, R., Konyecsni, W.M., Chakrabarty, A.M., and Misra, T.K. 1989. The algR gene, which regulates mucoidy in Pseudomonas aeruginosa, belongs to a class of environmentally responsive genes. J. Bacteriol. 171: 1278-1283. Drenkard, E. and Ausubel, F.M. 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416: 740-743.[CrossRef][Medline]
Ewing, B. and Green, P. 1998. Base-calling of automated sequencer traces using phred.II. Error probabilities. Genome Res. 8: 186-194. Gavin, A.C., Bosche, M., Krause, R., Grandi, P., Marzioch, M., Bauer, A., Schultz, J., Rick, J.M., Michon, A.M., and Cruciat, C.M., et al. 2002. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415: 141-147.[CrossRef][Medline] Goldberg, J.B. and Dahnke, T. 1992. Pseudomonas aeruginosa AlgB, which modulates the expression of alginate, is a member of the NtrC subclass of prokaryotic regulators. Mol. Microbiol. 6: 59-66.[CrossRef][Medline] Hobbs, M., Collie, E.S., Free, P.D., Livingston, S.P., and Mattick, J.S. 1993. PilS and PilR, a two-component transcriptional regulatory system controlling expression of type 4 fimbriae in Pseudomonas aeruginosa. Mol. Microbiol. 7: 669-682.
Ishimoto, K.S. and Lory, S. 1992. Identification of pilR, which encodes a transcriptional activator of the Pseudomonas aeruginosa pilin gene. J. Bacteriol. 174: 3514-3521. Kigawa, T., Muto, Y., and Yokoyama, S. 1995. Cell-free synthesis and amino acid-selective stable isotope labeling of proteins for NMR analysis. J. Biomol. NMR. 6: 129-134.[Medline]
Li, S., Armstrong, C.M., Bertin, N., Ge, H., Milstein, S., Boxem, M., Vidalain, P.O., Han, J.D., Chesneau, A., Hao, T., et al. 2004. A map of the interactome network of the metazoan C. elegans. Science 303: 540-543. Macfarlane, E.L., Kwasnicka, A., Ochs, M.M., and Hancock, R.E. 1999. PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Mol. Microbiol. 34: 305-316.[CrossRef][Medline] Masignani, V., Rappuoli, R., and Pizza, M. 2002. Reverse vaccinology: A genome-based approach for vaccine development. Expert Opin. Biol. Ther. 2: 895-905.[CrossRef][Medline]
McKevitt, M., Patel, K., Smajs, D., Marsh, M., McLoughlin, M., Norris, S.J., Weinstock, G.M., and Palzkill, T. 2003. Systematic cloning of Treponema pallidum open reading frames for protein expression and antigen discovery. Genome Res. 13: 1665-1674. McPhee, J.B., Lewenza, S., and Hancock, R.E. 2003.Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 50: 205-217.
Moss, J., Ehrmantraut, M.E., Banwart, B.D., Frank, D.W., and Barbieri, J.T. 2001. Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus. Infect. Immun. 69: 1185-1188. Murthy, T.V.S., Wu, W., Qiu, Q.Q., Shi, S., LaBaer, J., and Brizuela, L. 2004. Bacterial cell-free system for high-throughput protein expression and a comparative analysis of E. coli cell-free and whole cell expression systems. Prot. Exp. Purif. 36: 217-225.[CrossRef][Medline] Phizicky, E., Bastiaens, P.I., Zhu, H., Snyder, M., and Fields, S. 2003. Protein analysis on a proteomic scale. Nature 422: 208-215.[CrossRef][Medline] Potvin, E., Lehoux, D.E., Kukavica-Ibrulj, I., Richard, K.L., Sanschagrin, F., Lau, G.W., and Levesque, R.C. 2003. In vivo functional genomics of Pseudomonas aeruginosa for high-throughput screening of new virulence factors and antibacterial targets. Environ. Microbiol. 5: 1294-1308.[CrossRef][Medline] Ratjen, F. and Doring, G. 2003. Cystic fibrosis. Lancet 361: 681-369.[CrossRef][Medline] Reboul, J., Vaglio, P., Rual, J.F., Lamesch, P., Martinez, M., Armstrong, C.M., Li, S., Jacotot, L., Bertin, N., and Janky, R., et al. 2003. C. elegans ORFeome version 1.1: Experimental verification of the genome annotation and resource for proteome-scale protein expression. Nat. Genet. 34: 35-41.[CrossRef][Medline] Ritchings, B.W., Almira, E.C., Lory, S., and Ramphal, R. 1995. Cloning and phenotypic characterization of fleS and fleR, new response regulators of Pseudomonas aeruginosa which regulate motility and adhesion to mucin. Infect. Immun. 63: 4868-4876.[Abstract] Rodrigue, A., Quentin, Y., Lazdunski, A., Mejean, V., and Foglino, M. 2000. Two-component systems in Pseudomonas aeruginosa: Why so many? Trends Microbiol. 8: 498-504.[CrossRef][Medline] Stock, A.M., Robinson, V.L., and Goudreau, P.N. 2000. Two-component signal transduction. Annu. Rev. Biochem. 69: 183-215.[CrossRef][Medline] |